Insights On Enterprise Solutions
-
De-Risking The Aseptic Drug-Filling Process And Optimizing Production
4/17/2024
Aseptic drug-filling poses significant risks for manufacturers that can increase costs and timelines. Leveraging proven expertise and efficiency can ensure the production of safe, efficacious products.
-
A Rentschler Collaboration Story
4/17/2024
Learn how a collaboration between Cytiva and Rentschler Biopharma facilitates the efficient and flexible production of viral vectors.
-
Tips For Viral Vector Production
4/16/2024
Learn about how meticulous purification optimization can maximize recovery and impurity removal by leveraging scalable downstream technologies to meet regulatory and process economy requirements.
-
Address Current Challenges In Gene Therapy Viral Vector Manufacturing
4/16/2024
This article addresses key advancements at each step in the production of viral vectors — from maximizing titer output at scale upstream to optimized formulation compositions at fill/finish — to support commercial scale.
-
Unlocking The Potential Of Your Sterile Injectables With Exact SI-ence
4/16/2024
Sterile injectables present multiple hurdles on the path from early clinical phases to commercial. Learn how a partner with extensive capabilities and expertise can help streamline the path to market.
-
Maximizing Efficiency In Biopharma Process Development
4/16/2024
This powerful and easy to use batch planning strategy combines bioprocessing software and parallel bioreactors, enabling you to potentiate process development.
-
Protecting Your Intellectual Property Rights In Drug Manufacturing
4/15/2024
Being aware and proactive in addressing IP risks and challenges, especially for drug developers and sponsors operating in Asia, is critical. Delve into the IP landscape of several Asian countries.
-
Commercial Readiness with ImmunityBio's Bobby Reddy, M.D.
4/14/2024
This episode of the Business of Biotech begins with a personal story about my dad and the standard of care in bladder cancer, before shifting to the work that Dr. Bobby Reddy and his team at ImmunityBio are doing to change that standard of care. They're painfully close. Dr. Reddy, Chief Medical Officer at ImmunityBio, gives us a long look behind the curtain at the commercial preparations the company is making as its lead Phase 3 candidate, Anktiva, nears the goal line in non-muscle invasive bladder cancer (NMIBC).
-
Ophthalmic Drug Delivery
4/11/2024
Explore the challenges to effective delivery of drugs to the eye, the intricacies of ophthalmic drug delivery, and the advantages of nanoparticles as an enabling technology for ocular drug-delivery systems.
-
Why The FDA General Calibration Requirements Are Not Enough
4/10/2024
Calibration is a niche industry that is not well understood by many. By choosing an ISO 17025-accredited organization, companies can benefit from external auditing and adherence to accepted standards.